Skip to main content
. 2020 Oct 7;124(1):237–246. doi: 10.1038/s41416-020-01092-0

Table 2.

Biomarkers associated with PFS and OS in the lenvatinib-plus-everolimus arm, as determined by HR.

Marker Cut-off Low group High group Log-rank P value Direction of HR: high/low
Quantile Value n MST n MST With FDR HR (95% CI)
Association with PFS
 ANG-2 0.5 6.800 μg/L 27 20.1 21 5.9 0.0351 0.1508 2.360 (1.040–5.355)
 HGF 0.5 7.350 μg/L 28 20.1 20 5.6 0.0264 0.1508 2.550 (1.088–5.974)
 IL-18 0.5 264.0 ng/L 28 14.7 20 5.6 0.0317 0.1508 2.418 (1.058–5.526)
 IL-18BP 0.5 17.0 μg/L 24 17.5 24 6.9 0.0305 0.1508 2.431 (1.059–5.580)
 M-CSF 0.5 0.9650 μg/L 28 14.7 20 7.4 0.1144 0.3088 1.904 (0.845–4.288)
 MIG 0.5 1250 ng/L 30 20.1 18 7.4 0.0299 0.1508 2.506 (1.062–5.914)
 TIMP-1 0.5 199.0 μg/L 26 14.7 22 5.6 0.0392 0.1508 2.326 (1.023–5.291)
 VEGF 0.5 305.0 ng/L 29 14.7 19 11.2 0.2526 0.5247 1.597 (0.711–3.587)
Association with OS
 ANG-2 0.5 6.800 μg/L 27 NE 21 21.7 0.003 0.0137 3.005 (1.402–6.442)
 HGF 0.5 7.350 μg/L 28 32.2 20 20.5 0.0081 0.0258 2.592 (1.249–5.377)
 IL-18 0.5 264.0 ng/L 28 32.1 20 20.7 0.0163 0.0367 2.376 (1.149–4.915)
 IL-18BP 0.5 17.00 μg/L 24 32.2 24 18.4 0.0008 0.0073 3.469 (1.605–7.501)
 M-CSF 0.5 0.9650 μg/L 28 NE 20 14.5 0.0002 0.0044 3.765 (1.781–7.959)
 MIG 0.5 1250 ng/L 30 25.5 18 25.5 0.9668 0.9668 0.985 (0.472–2.056)
 TIMP-1 0.5 199.0 μg/L 26 NE 22 16.1 0.0003 0.0044 3.770 (1.741–8.162)
 VEGF 0.5 305.0 ng/L 29 32.2 19 20.5 0.0021 0.0137 2.993 (1.441–6.213)

Biomarkers most strongly associated with PFS or OS (by HR), respectively, are shaded grey.

ANG-2 angiopoietin-2, FDR false discovery rate, HGF hepatocyte growth factor, HR hazard ratio, IL-18 interleukin-18, IL-18BP interleukin-18 binding protein, M-CSF macrophage colony-stimulating factor, MIG monokine induced by gamma interferon, MST median survival time, NE not estimable, OS overall survival, PFS progression-free survival, TIMP-1 tissue inhibitor of metalloproteinase-1, VEGF vascular endothelial growth factor.